Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G: High-dose-rate stereotactic body radiation therapy for post radiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Pract Radiation Oncology 2015 Nov-Dec;5(6):e615-23.doi: 10.1016/j.prro.2015.04.009.Epub 2015 Jun6
Dowlatshahi M, Do L, Shirazi R, Mehrany K, Salari A, Huan L, Kagan AR:
Merkel Cell Carcinoma Treated with Wide Local Excision with or without Radiotherapy: A Multi-Institutional Retrospective Analysis. Paper submitted for publication
Shirazi R, Goldfarb PM, Fuller DB, Sanati H: CyberKnife Stereotactic Body Radiation Therapy for Palliation and Local Control in Patients with Advanced Pancreatic Cancer: A Retrospective Review. Journal of Clinical Oncology 29: 2011 (suppl; abstract e14506)
Fuller DB, Shirazi R, Naitoh J, Mardirossian G: Virtual HDR SBRT for Localized Prostatic Carcinoma: Efficacy and Quality of Life Assessment. Abstract accepted for poster presentation at the American Society for Radiation Oncology 53rd Annual Meeting, Miami Beach, Florida, October 2011
Shirazi R, Goldfarb P, Fuller D, Smith, D, Tova Y, Mansy G, Giap H, Sanati H. Hypofractionated CyberKnife Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer. Abstract presented at the 2011 CyberKnife Robotic Radiosurgery Summit, San Francisco, February 2011
Giap HB, Fuller DB, Mardirossian G, Muniruzzaman MM, Smith DE, Shirazi R, Mansy GJ, Tova Y, Ijaz T, Lin R. CyberKnife Treatment for Posterior Lung Tumor: Supine versus Prone Position? Abstract presented at the 9th Annual CyberKnife Scientific Meeting. Dallas, Texas, March 2010
Giap HB, Fuller DB, Mardirossian G, Muniruzzaman MM, Smith DE, Mansy GJ, Tova Y, Shirazi R, Ijaz T, Lin R. Partial Breast Irradiation with CyberKnife: Solutions to Overcome the Technical Issues to the First Patient Treatment. Abstract presented at the 9th Annual CyberKnife Scientific Meeting. Dallas, Texas, March 2010
Mierzwa ML, Barrett WL, Redmond K, Shirazi R, Kastle A, Kumar N, Buncher R: Randomized trial to assess the efficacy of intraoperative steroid use in decreasing acute urinary retention after transperineal radioactive iodine-125 implantation for prostate cancer. Cancer 2008 November 1; 113(9): 2605-9
Mierzwa ML, Barrett WL, Redmond KP, Shirazi R, Kastl A: A Phase III Randomized Trial to Assess the Efficacy on Intraoperative Steroid Use in Decreasing Acute Urinary Retention Following Transperineal Radioactive Seed Implantation for Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics 2007 November 1; Vol 69 (3 Supplement) S113-S114
Mishra MV, Shirazi R, Barrett WL: Incidence and Clinical Course of Hemorrhagic Radiation Proctitis after Iodine-125 Prostate Brachytherapy. Clinics in Genitourinary Cancer 2007 September; 5 (6): 397-400
William Barrett, William Kassing, Reza Shirazi. Efficacy of Brachytherapy for prostate cancer in African Americans compared with Caucasians. Brachytherapy 3 (2004): 30-33
R. Shirazi, M. Mishra, W. Barrett. Prostate Specific Antigen Nadir after
brachytherapy alone for treatment of prostate cancer; how low does it have
to go? (manuscript) Submitted to Brachytherapy
R. Shirazi, M. Mishra, A. Kleimeyer, W. Kassing, W. Barrett. Neoadjuvant
hormonal therapy plus brachytherapy vs. brachytherapy alone for patients
with prostate cancer: A single institution retrospective study. Journal of
Clinical Oncology, 2004 ASCO Annual Meeting Proceedings Vol. 23: 423 (4674)
R. Shirazi, R. C. Buncher, Y. Gao, W. L. Barrett.
Assessing the impact of alternative definitions of biochemical failure in prostate cancer patients treated with brachytherapy alone. Journal of Clinical Oncology, 2006 ASCO
Annual Meeting Proceedings, presented
R. Shirazi, A. Puthawala, A. Shrama, N. Syed. HDR for recurrent/persistent Head and Neck Cancer, Long Beach Memorial experience. 2006 ACRO Annual Meeting, Florida (scholarship recipient), presented
M. V. Mishra, R. Shirazi, K. Hertzfeld, W. Barrett. What PSA nadir after prostate brachytherapy is associated with biochemical disease control? Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings Vol. 23, No 16S: 431s (4716)
M. V. Mishra, R. Shirazi, W. Barrett. Incidence and clinical course of hemorrhagic radiation proctitis following 125I prostate Brachytherapy. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (to be published), presented
A. Nagavi, R. Shirazi, N. Dunlap, W. Barrett. Age as a prognostic factor for prostate cancer patients treated with brachytherapy.(manuscript) Submitted to Brachytherapy
A. Nagavi, R. Shirazi, N. Dunlap, W. Barrett. Age as a prognostic factor for prostate cancer patients treated with brachytherapy. Journal of Clinical Oncology,2005 ASCO Annual Meeting Proceedings Vol. 23, No 16S: 435s (4731)
K. E. Hertzfeld, R. Shirazi, W. Barrett. Efficacy of brachytherapy for prostate cancer in organ transplant patients. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings Vol. 23, No 16S: 452s (4797)
N. Dunlap, R. Shirazi, A. Naghavi, W. Barrett. The prognostic importance of Biopsy proven unilateral vs. bilateral disease in patients treated with I-125 seed implant for localized prostate cancer : A single institution retrospective study. ASCO Annual Meeting Proceedings Vol. 23 (2004): 423 (4673)
R. Shirazi, E. Dessner, E. Kim, C. Peña-Rasgado & H. Rasgado-Flores. Second messenger stimulation of Na/Mg exchange in skeletal muscle. FASEB J. 13: A401(350.3), 1999.
R. Shirazi, R. Modak, J. Tie, P. Yee, J. DeSantiago, C. Peña-Rasgado, H. Gonzalez-Serratos and H. Rasgado-Flores. Modulation of extracellular Mg-dependent Na efflux in skeletal muscle. FASEB J. 12: A548(3184), 1998.
